Alizyme Therapeutics' investigational ulcerative colitis treatment Colal-Pred has failed to meet one of its primary endpoints in a pivotal Phase III trial. Colal-Pred, a colonic-release formulation of prednisolone, showed inferior efficacy to conventional prednisolone in the trial.
Alizyme Therapeutics' investigational ulcerative colitis treatment Colal-Pred has failed to meet one of its primary endpoints in a pivotal Phase III trial. Colal-Pred, a colonic-release formulation of prednisolone, showed inferior efficacy to conventional prednisolone in the trial.
Shares in the UK-listed biotech company fell by 50% to 7.76p on the London Stock Exchange on July 24th, following...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
